In this study, 21.6% ofthe patients were Group 1 PHT, pulmonary arterialhypertension, and 1.6% of the patients were classifiedas Group 3 PHT, a result of lung disease.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:We read the recent article published by Hacıyev etal.[1] about their center’s experience with pulmonaryhypertension (PHT) with great interest.
📊
Key Findings & Data:It was notedthat left-heart disease PHT, defined by the WorldHealth Organization as Group 2, is the most commontype of PHT and that valvular disease is the most frequentcause of Group 2 PHT.
💡
Conclusion & Impact:In this study, 21.6% ofthe patients were Group 1 PHT, pulmonary arterialhypertension, and 1.6% of the patients were classifiedas Group 3 PHT, a result of lung disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
We read the recent article published by Hacıyev etal.[1] about their center’s experience with pulmonaryhypertension (PHT) with great interest. It was notedthat left-heart disease PHT, defined by the WorldHealth Organization as Group 2, is the most commontype of PHT and that valvular disease is the most frequentcause of Group 2 PHT. In this study, 21.6% ofthe patients were Group 1 PHT, pulmonary arterialhypertension, and 1.6% of the patients were classifiedas Group 3 PHT, a result of lung disease.
🔖
Cite This Article
Okşul, M., Şener, Y. Z., Hekimsoy, V. (2022). Right heart catheterization datas may not reflect the pulmonary hypertension epidemiology accurately. Türk Kardiyoloji Derneği Arşivi, Cilt: 47 - Sayı: 2, 157–157. https://ajindex.com/articles/632073
Hacıyev R, Ünlü S, Yalçın MR, Taçoy G, Çengel A. Pulmonary hypertension spectrum: 16 years of experience from a single center. Turk Kardiyol Dern Ars 2018;46:667–74. [Article in Turkish] 2. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67–119.